Lan Beppu

Disease relapse after haematopoietic stem cell transplantation: Risk factors and treatment

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia

Cancer drug resistance: an evolving paradigm

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Cancer genes and the pathways they control

Targeting cancer with small molecule kinase inhibitors

Chemotherapy and the war on cancer

Chronic Myelogenous Leukemia

Hematopoietic Stem-Cell Transplantation

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance

Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

Diagnosing and Managing Advanced Chronic Myeloid Leukemia

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation

Predictors of relapse and overall survival in Philadelphia chromosome–positive acute lymphoblastic leukemia after transplantation